Peptides are one of the most successful drug classes in modern medicine, and the unapproved end of the market is where the risk sits. More than 80 peptide drugs have reached the market, and semaglutide cut major cardiovascular events by 20% in SELECT. Compounds such as BPC-157 and TB-500 have extensive animal data and almost no human trials. The documented serious harms trace mostly to product origin and quality.
Key points
- More than 80 peptide drugs have reached the market. In the SELECT trial, semaglutide cut the risk of major cardiovascular events by 20% [1][2].
- In the US, 12% of adults currently use a GLP-1 and nearly one in five users turns to compounded versions [3][4].
- Tirzepatide and semaglutide account for most of the revenue of the two companies that make them [5][6].
- A PubMed search found no published deaths attributed to peptides such as BPC-157 or TB-500, although human safety data are lacking. Recent deaths in Mexico are preliminarily linked to contaminated IV drips, not peptides [8][10].
US status (October 2026): Status differs by compound. See the peptide status tracker.
Peptides are a proven drug class
Since insulin, almost a century ago, more than 80 peptide drugs have reached the market for diabetes, cancer, osteoporosis, multiple sclerosis, HIV and chronic pain [1]. Semaglutide does more than reduce weight. In the randomized SELECT trial, with 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes, it reduced the risk of cardiovascular death, nonfatal heart attack or nonfatal stroke by 20% (HR 0.80) [2]. Bremelanotide (PT-141) and tesamorelin are also FDA-approved for specific indications, and elamipretide (SS-31) received accelerated approval for Barth syndrome [12][13][14].
- More than 80: approved peptide drugs [1]
- 1 in 8: US adults currently on a GLP-1 [3]
- 20%: reduction in major cardiovascular events with semaglutide in SELECT [2]
US patients have already decided
In November 2025, 12% of US adults said they were currently using a GLP-1 and 18% had used one at some point [3]. According to a Gallup survey, nearly one in five users relies on a compounded version not approved by the FDA [4]. The approved products dominate their makers’ books: tirzepatide (Mounjaro and Zepbound) was more than half of Eli Lilly’s 2025 revenue [5], and Novo Nordisk’s three semaglutide products (Ozempic, Wegovy and Rybelsus) were roughly three quarters of its 2025 revenue [6]. For the rules on compounded versions, see compounded GLP-1 after the shortage.
Beyond GLP-1s, unapproved peptides are now part of the public conversation. The US Health Secretary, Robert F. Kennedy Jr., said he has used them “with really good effect on a couple of injuries” [15]. In July 2026 the FDA advisory committee voted in favor of six of seven peptides for compounding. One committee member who voted yes, Dr. Haleem Mohammed, summed it up: “Our patients want peptides” [7]. Details are in What the FDA actually said and Why doctors and patients defend peptides. A committee vote is not a listing. Check each compound’s current position on the status tracker before it reaches a protocol.
The map runs from proven to preclinical
| Area | Compounds | Evidence |
|---|---|---|
| Metabolism and weight | GLP-1, GIP, amylin | Strongest in the field: phase 3 trials and cardiovascular outcomes. See GLP-1s: muscle, rebound, eyes and pancreas and After semaglutide |
| Growth hormone axis | CJC-1295, ipamorelin, tesamorelin | In human studies, CJC-1295 raised GH and IGF-1. Tesamorelin is approved. See the GH and IGF-1 debate and tesamorelin |
| Repair and recovery | BPC-157, TB-500 | Extensive animal evidence. Human trials still pending. See BPC-157 and TB-500 |
| Skin | GHK-Cu | Topical trials with mixed results: positive in diabetic ulcers, no better than placebo in venous ulcers. The injectable route lacks human data. See GHK-Cu |
| Sexual and reproductive health | PT-141, kisspeptin | Bremelanotide approved. Kisspeptin has small but rigorous IVF studies. See kisspeptin and PT-141 |
| Cognition and sleep | Semax, Selank | Semax is a registered drug in Russia. See Semax, Selank and DSIP |
| Longevity | Epitalon, MOTS-c, NAD+, SS-31 | Promising biology. SS-31 has an accelerated approval for Barth syndrome. See longevity |
The safety record points to product origin
Approved peptides have safety profiles well characterized in large trials. In SELECT, 16.6% of patients on semaglutide and 8.2% on placebo stopped treatment because of adverse events [2].
For unapproved peptides, a PubMed search found no published deaths attributed to BPC-157, TB-500, GHK-Cu or similar compounds. A systematic review found no clinical safety data: the problem is the lack of studies rather than a demonstrated harm signal [8]. Documented serious events are few, but they exist. In the most publicized case, RAADfest in 2025, two attendees were hospitalized in critical condition after receiving injections of peptide mixtures [9]. Both had to be intubated and both have since recovered. The Nevada pharmacy board could not determine the cause, and in February 2026 it fined those who offered the injections [19]. The FDA mentions a few serious events in studies: serious adverse events including a death with intravenous ipamorelin in a published gastric-motility study, with no further detail, and deaths among critically ill patients in GHRP-2 studies, with causality not established [16].
The international tragedies have a different cause. For the 8 deaths in Hermosillo, Sonora (Mexico), the health authorities’ preliminary hypothesis is that the IV vitamin drips may have been contaminated with bacteria [10]. In the counterfeit “Ozempic” pens Panama’s health ministry (MINSA) warned about in 2023, detected in Austria, the Austrian regulator linked the hospitalizations to the insulin they presumably contained [11]. The lesson: the real risk lies in the product’s origin and quality. See what is really in the vial, and use the peptide supplier diligence checklist before you order.
What happened in Panama, and why US clinics should care
Panama shows the same demand. According to MINSA, 72% of Panamanian adults have overweight or obesity [17]. In 2025 MINSA investigated the use of Ozempic for weight loss, found it being sold through social media and warned about the risk of buying medicines online without a prescription [18]. The legal framework there differs from the US. It is summarized in a physician’s legal map in Panama.
The relevance for you is the supply chain. Counterfeit pens, social-media sales and contaminated infusions cross borders, and patients who travel for treatment come back to your clinic.
What this means for your practice
Patients will arrive with these questions, or with these products. The clinician who knows the evidence, for and against, becomes their point of reference. If they do not find that in your clinic, they will look for it on Instagram. Start with the approved drugs, check every other compound against the status tracker, and keep anything labeled research use only out of patient care. If you are building a structured program, see peptide programs.
References
- Muttenthaler M, et al. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. PMID 33536635. Link
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-32. PMID 37952131. Link
- KFF. Poll: 1 in 8 adults say they are currently taking a GLP-1 drug for weight loss, diabetes or another condition, even as half say the drugs are difficult to afford. 14 November 2025. Link
- Bilodeau K. Compounders maintain a firm grip on the GLP-1 market (Gallup survey). BioPharma Dive. 17 July 2026. Link
- Eli Lilly and Company. Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance (press release). 4 February 2026. Link
- Pharmcube. Novo Nordisk 2025 revenue and semaglutide sales (headline figures omitted). 2026. Link
- Healio. FDA committee recommends looser restrictions for several peptides. 24 July 2026. Link
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. PMID 40756949. Link
- ProPublica. Peptide injections at RAADfest (two women hospitalized). 29 July 2025. Link
- Publimetro México. Cofepris revela posible causa de muertes por sueros vitaminados que dejaron ocho fallecidos. 9 de abril de 2026. Link
- Ministerio de Salud de Panamá, DNFD. Comunicado 067/23/DNFD: Advertencia sobre la falsificación del medicamento Ozempic (presentación alemana). 31 de octubre de 2023. Link
- U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557, 2019. Link
- U.S. Food and Drug Administration. Egrifta (tesamorelin for injection) prescribing information. NDA 022505, 2010. Link
- U.S. Food and Drug Administration. FDA grants accelerated approval to first treatment for Barth syndrome. 19 September 2025. Link
- Boston Globe. FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures. 15 April 2026. Link
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Link
- Telemetro. ¡Advertencia! MINSA revela que el 72% de los adultos en Panamá enfrentan obesidad. 7 de enero de 2025. Link
- Vega Loo M. Minsa investiga el mal uso del Ozempic en Panamá: no es un medicamento para bajar de peso. La Estrella de Panamá. 12 de julio de 2025. Link
- Damon A. Nevada Regulators Fine Peptide Providers at Anti-Aging Festival Where Two Women Became Critically Ill. ProPublica. 13 March 2026. Link
This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.